Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C
- 26 April 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (9) , 6940-6952
Abstract
KRAS is an archetypal high-value intractable oncology drug target. The glycine to cysteine mutation at codon 12 represents an Achilles heel that has now rendered this important GTPase druggable. Herein, we report our structure-based drug design approach that led to the identification of 21, AZD4625, a clinical development candidate for the treatment of KRASG12C positive tumors. Highlights include a quinazoline tethering strategy to lock out a bio-relevant binding conformation and an optimization strategy focused on the reduction of extrahepatic clearance mechanisms seen in preclinical species. Crystallographic analysis was also key in helping to rationalize unusual structure-activity relationship in terms of ring size and enantio-preference. AZD4625 is a highly potent and selective inhibitor of KRASG12C with an anticipated low clearance and high oral bioavailability profile in humans.Keywords
This publication has 21 references indexed in Scilit:
- Water, water, everywhere… It's time to stop and thinkDrug Discovery Today, 2016
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomasNature Genetics, 2016
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive StateCancer Discovery, 2016
- Genomic analyses identify molecular subtypes of pancreatic cancerNature, 2016
- Water Sites, Networks, And Free Energies with Grand Canonical Monte CarloJournal of the American Chemical Society, 2015
- The Role of Extrahepatic Metabolism in the Pharmacokinetics of the Targeted Covalent Inhibitors Afatinib, Ibrutinib, and NeratinibDrug Metabolism and Disposition, 2015
- Strategies to Calculate Water Binding Free Energies in Protein–Ligand ComplexesJournal of Chemical Information and Modeling, 2014
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactionsNature, 2013
- Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)Cancer Research, 2010
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003